Analogs for the treatment of disease
AssigneeInsilico Medicine IP Limited
InventorsAleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
Life of this patent
Estimating the term…
Abstract
The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.
Claims28
A compound represented by Formula (IIA),
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is piperazine, wherein the piperazine is optionally substituted with one or more substituents independently selected at each occurrence from oxo, —S(O2)NH2, and C1-10 alkyl, wherein the C1-10 alkyl is optionally substituted with one or more substituents independently selected at each occurrence from hydroxy, halogen, oxo, and —NH2;
- R3 is phenyl, wherein the phenyl is optionally substituted with one or more halogen;
- and
- R4 is
A pharmaceutical composition comprising (i) a compound represented by Formula (IIA),
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is piperazine, wherein the piperazine is optionally substituted with one or more substituents independently selected at each occurrence from oxo, —S(O2)NH2, and C1-10 alkyl, wherein the C1-10 alkyl is optionally substituted with one or more substituents independently selected at each occurrence from hydroxy, halogen, oxo, and —NH2;
- R3 is phenyl, wherein the phenyl is optionally substituted with one or more halogen;
- and
- R4 is
- and
- (ii) a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.